Remifentanil

Generic Name
Remifentanil
Brand Names
Ultiva
Drug Type
Small Molecule
Chemical Formula
C20H28N2O5
CAS Number
132875-61-7
Unique Ingredient Identifier
P10582JYYK
Background

Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.

Indication

For use during the induction and maintenance of general anesthesia.

Associated Conditions
-
Associated Therapies
Immediate postoperative analgesia therapy, Induction and Maintenance of General Anesthesia, Monitored anesthesia care sedation
Clinical Trials
Related News

Remifentanil in Extracorporeal Shock Wave Lithotripsy

Phase 4
Completed
Conditions
Kidney Calculi
First Posted Date
2011-10-17
Last Posted Date
2011-10-17
Lead Sponsor
University of Roma La Sapienza
Target Recruit Count
228
Registration Number
NCT01452880
Locations
🇮🇹

Policlinico Umberto I, Rome, Italy/RM, Italy

Efficacy of Alkalinized Lidocaine Compared to Remifentanil on the Incidence of Coughing During Emergence of Anesthesia

Not Applicable
Completed
Conditions
Cough
Anesthesia
Interventions
Drug: Remifentanil
Drug: Alkalinized lidocaine
First Posted Date
2011-10-14
Last Posted Date
2012-10-29
Lead Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Target Recruit Count
85
Registration Number
NCT01451840
Locations
🇨🇦

Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada

Pregabalin and Remifentanil - Analgesia and Ventilation

First Posted Date
2011-08-18
Last Posted Date
2014-09-12
Lead Sponsor
Oslo University Hospital
Target Recruit Count
12
Registration Number
NCT01419405
Locations
🇳🇴

Oslo Universitetssykehus, Rikshospitalet, Oslo, Norway

Safety Evaluation of Dexmedetomidine for EBUS-TBNA

First Posted Date
2011-06-27
Last Posted Date
2013-02-28
Lead Sponsor
Maisonneuve-Rosemont Hospital
Target Recruit Count
60
Registration Number
NCT01381627
Locations
🇨🇦

Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada

Comparison of Dexmedetomidin and Remifentanil for the Effect on Airway Reflex and Hemodynamic Response During Emergence in Patients Undergoing Craniotomy

First Posted Date
2011-06-03
Last Posted Date
2014-07-01
Lead Sponsor
Yonsei University
Target Recruit Count
74
Registration Number
NCT01365923
Locations
🇰🇷

Severance Hospital, Seoul, Korea, Republic of

Alfentanil Versus Remifentanil in Patient-controlled Sedation During Endoscopic Retrograde Cholangiopancreatography (ERCP)

First Posted Date
2011-05-09
Last Posted Date
2012-07-06
Lead Sponsor
Helsinki University Central Hospital
Target Recruit Count
81
Registration Number
NCT01350037
Locations
🇫🇮

Helsiki University Central Hospital,Meilahti Hospital,Endoscopy unit, Helsinki, Uusimaa, Finland

Safety of Remifentanil Infusion

Phase 4
Completed
Conditions
Urinary Tract Problem
Interventions
Drug: remifentanil
First Posted Date
2011-02-25
Last Posted Date
2012-06-25
Lead Sponsor
Diskapi Teaching and Research Hospital
Target Recruit Count
42
Registration Number
NCT01303627
Locations
🇹🇷

Ministry of Health Diskapi Yildirim Beyazit Research and Training Hospital departement of 1. Anesthesiology, Ankara, Turkey

Sedation in Endoscopic Retrograde Cholangiopancreatography (ERCP) With or Without Opioids

Not Applicable
Completed
Conditions
Chronic Pain
Interventions
Drug: Remifentanil
Drug: Normal saline
Drug: Fentanyl
First Posted Date
2011-02-25
Last Posted Date
2013-08-05
Lead Sponsor
University of Athens
Target Recruit Count
180
Registration Number
NCT01304342
Locations
🇬🇷

Department of Anesthesiology, Aretaieio Hospital, Athens, Greece

ULTIVA Post Marketing Surveillance

Completed
Conditions
Analgesia
Interventions
Drug: Remifentanil
First Posted Date
2011-02-18
Last Posted Date
2017-07-06
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
775
Registration Number
NCT01299584

Non-opioid Analgesia for Fast-track Surgery

Not Applicable
Completed
Conditions
Pain
Interventions
Drug: Esmolol
Drug: Remifentanil
First Posted Date
2011-01-13
Last Posted Date
2013-03-27
Lead Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Target Recruit Count
40
Registration Number
NCT01275911
Locations
🇨🇦

Montreal General Hospital, McGill University Health Centre, Montreal, Quebec, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy